April 16th 2020 11:00 am EDT | 4 PM GMT | 5 PM CET
Patents, Vaccines, and Viruses: A conversation about the role of IP in the age of COVID-19
Loading...
Register now for our April 16th webinar. Join us at 11 AM EDT | 4 PM GMT | 5 PM CET
As the coronavirus pandemic spreads across the globe, putting unprecedented pressure on social, health, and economic systems, scientists are working around the clock to develop vaccine candidates in record time.
Intellectual property in the form of patented biosequences and chemical structures may play a role in inhibiting or antagonizing the virus factor to help researchers better understand the disease and bring treatments to fruition.
These extraordinary, collaborative, and fast-tracked scenarios playing out in labs all over the world raise some important questions for the biopharma patent community with regard to the state of innovation for the public good, today and in the future.
Intellectual property in the form of patented biosequences and chemical structures may play a role in inhibiting or antagonizing the virus factor to help researchers better understand the disease and bring treatments to fruition.
These extraordinary, collaborative, and fast-tracked scenarios playing out in labs all over the world raise some important questions for the biopharma patent community with regard to the state of innovation for the public good, today and in the future.
We will be covering the following topics:
-
How are patent gene sequences and chemical structures impacting vaccine development today versus a decade ago? What role will they play in the future?
-
What can past responses to global pandemics teach us about the importance and management of intellectual property now?
-
What impact has the current climate had on IP activity more generally across the globe and how can patent practitioners guide organizations to create and maintain innovation momentum?
About our speakers:
Gaby L. Longsworth, Ph.D.
Director, Sterne, Kessler, Goldstein & Fox P.L.L.C.
Gaby L. Longsworth, Ph.D., is a director in Sterne Kessler's Biotechnology & Chemical Practice Group and is the chairperson of the firm's Diversity Committee. She is sought out by biopharmaceutical companies world-wide for her insights and knowledge of intellectual property and Hatch-Waxman law.
In her practice, Gaby counsels international biopharmaceutical clients in all areas of patent procurement and strategy, including domestic and foreign patent preparation and lifecycle management. Her practice is primarily focused on biotherapeutics, small molecules, biologics, immunotherapy, antibody technologies, microbiome-based technologies, synthetic biology, DNA amplification/PCR, diagnostics, vaccines, viral vectors and drug delivery.
Gaby earned a J.D. at Georgetown University Law Center, a Ph.D. in human genetics and molecular biology at The Johns Hopkins University and a B.S. in molecular biology from the Florida Institute of Technology. She is fluent in Dutch.
In her practice, Gaby counsels international biopharmaceutical clients in all areas of patent procurement and strategy, including domestic and foreign patent preparation and lifecycle management. Her practice is primarily focused on biotherapeutics, small molecules, biologics, immunotherapy, antibody technologies, microbiome-based technologies, synthetic biology, DNA amplification/PCR, diagnostics, vaccines, viral vectors and drug delivery.
Gaby earned a J.D. at Georgetown University Law Center, a Ph.D. in human genetics and molecular biology at The Johns Hopkins University and a B.S. in molecular biology from the Florida Institute of Technology. She is fluent in Dutch.
Doreen Alberts
Senior Director of Product Strategy and Commercial Planning, Theravance Biopharma US, Inc.
Doreen Alberts is the Senior Director of Product Strategy and Commercial Planning at Theravance Biopharma US, Inc. (TBPH). TBPH is a pharmaceutical company focused in the areas of inflammation and immunology, with a pipeline of internally discovered programs targeted to address significant patient needs. Doreen is responsible for managing the following functions at TBPH: patent and literature searching, library services, document delivery, competitive intelligence, medical information and end-user education and training.
Doreen has a BA in Chemistry, minor in Economics from the University of California, San Diego. Prior to working for Theravance, Doreen worked for SmithKline Beecham (now GSK) as a medicinal chemist for 11 years, and as an information analyst for 2 years. In September 2019, she earned her Artificial Intelligence Strategy Certificate from the University of California Berkeley School of Information.
Doreen has a BA in Chemistry, minor in Economics from the University of California, San Diego. Prior to working for Theravance, Doreen worked for SmithKline Beecham (now GSK) as a medicinal chemist for 11 years, and as an information analyst for 2 years. In September 2019, she earned her Artificial Intelligence Strategy Certificate from the University of California Berkeley School of Information.
Andrea Davis
Managing Director, Bodkin IP
Andrea Davis is an accomplished intellectual property professional with expertise in medical devices and the mechanical sector. One of the first and few Qualified Patent Information Professionals (QPIPs) in the world, Andrea's extensive experience as a patent analyst for in-house as well as outside patent research firms has shaped an understanding of patent process requirements and the importance of quality in patent research. Andrea is passionate about the science of patent searching and actively involved in Patent Information Users Group (PIUG), as well as the cofounder of the Patent Olympiad. Andrea is also volunteering in the efforts of establishing a certification for patent information professionals.
Tony Trippe
Managing Director, Patinformatics
Anthony (Tony) Trippe is Managing Director of Patinformatics, LLC. He is also an Adjunct Professor of IP Management and Markets at Illinois Institute of Technology, teaching a course on patent analysis and tools, and how they pertain to an organization’s IP strategy. Prior to his career in chemical and patent information retrieval and analysis, Mr. Trippe was a synthetic organic chemist and culminated his career on the bench by synthesizing the first five-hundred gram clinical patch of Viracept under GMP conditions, which went on to become Pfizer’s blockbuster HIV protease inhibitor drug. Mr. Trippe is an influential thought leader in the patent strategy, and analysis space, and has been named one of the Top 300 IP Strategists by IAM Magazine.
Sandeep Thakur
Head of Biopharma IP Product Management, Clarivate Analytics
Sandeep Thakur is the Head of Biopharma IP Product Management at Clarivate Analytics. In this role, Sandeep has worked on the development of IP content, search and analytics capabilities to empower innovation professionals from the pharmaceutical & biotech industries across the innovation lifecycle from idea to commercialization. He’s always interested in talking about patent search challenges and the tools to tackle them. Prior to this role, Sandeep has held multiple roles across Asia, Europe and North Americas fostering innovation across industries leveraging the power of information and technology. Sandeep has a Bachelor in Computer Engineering from Mumbai University and a MBA from the Indian Institute of Management, Ahmedabad.